Biogen Statistics
Total Valuation
Biogen has a market cap or net worth of $20.85 billion. The enterprise value is $25.19 billion.
| Market Cap | 20.85B |
| Enterprise Value | 25.19B |
Important Dates
The next estimated earnings date is Wednesday, April 23, 2025, before market open.
| Earnings Date | Apr 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Biogen has 146.37 million shares outstanding. The number of shares has increased by 0.21% in one year.
| Current Share Class | 146.37M |
| Shares Outstanding | 146.37M |
| Shares Change (YoY) | +0.21% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.16% |
| Owned by Institutions (%) | 91.16% |
| Float | 146.00M |
Valuation Ratios
The trailing PE ratio is 12.74 and the forward PE ratio is 9.01. Biogen's PEG ratio is 2.62.
| PE Ratio | 12.74 |
| Forward PE | 9.01 |
| PS Ratio | 2.14 |
| Forward PS | 2.23 |
| PB Ratio | 1.24 |
| P/TBV Ratio | 38.19 |
| P/FCF Ratio | 7.66 |
| P/OCF Ratio | 7.25 |
| PEG Ratio | 2.62 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.41, with an EV/FCF ratio of 9.25.
| EV / Earnings | 15.43 |
| EV / Sales | 2.60 |
| EV / EBITDA | 8.41 |
| EV / EBIT | 10.85 |
| EV / FCF | 9.25 |
Financial Position
The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.40.
| Current Ratio | 1.35 |
| Quick Ratio | 0.77 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | 2.15 |
| Debt / FCF | 2.47 |
| Interest Coverage | 9.28 |
Financial Efficiency
Return on equity (ROE) is 10.36% and return on invested capital (ROIC) is 6.36%.
| Return on Equity (ROE) | 10.36% |
| Return on Assets (ROA) | 5.29% |
| Return on Invested Capital (ROIC) | 6.36% |
| Return on Capital Employed (ROCE) | 10.31% |
| Revenue Per Employee | $1.27M |
| Profits Per Employee | $214,622 |
| Employee Count | 7,605 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 0.93 |
Taxes
In the past 12 months, Biogen has paid $273.80 million in taxes.
| Income Tax | 273.80M |
| Effective Tax Rate | 14.37% |
Stock Price Statistics
The stock price has decreased by -34.27% in the last 52 weeks. The beta is 0.01, so Biogen's price volatility has been lower than the market average.
| Beta (5Y) | 0.01 |
| 52-Week Price Change | -34.27% |
| 50-Day Moving Average | 142.07 |
| 200-Day Moving Average | 178.77 |
| Relative Strength Index (RSI) | 50.37 |
| Average Volume (20 Days) | 1,814,527 |
Short Selling Information
The latest short interest is 3.88 million, so 2.65% of the outstanding shares have been sold short.
| Short Interest | 3.88M |
| Short Previous Month | 3.74M |
| Short % of Shares Out | 2.65% |
| Short % of Float | 2.66% |
| Short Ratio (days to cover) | 1.85 |
Income Statement
In the last 12 months, Biogen had revenue of $9.68 billion and earned $1.63 billion in profits. Earnings per share was $11.18.
| Revenue | 9.68B |
| Gross Profit | 7.37B |
| Operating Income | 2.32B |
| Pretax Income | n/a |
| Net Income | 1.63B |
| EBITDA | 3.00B |
| EBIT | 2.32B |
| Earnings Per Share (EPS) | $11.18 |
Balance Sheet
The company has $2.38 billion in cash and $6.72 billion in debt, giving a net cash position of -$4.34 billion or -$29.66 per share.
| Cash & Cash Equivalents | 2.38B |
| Total Debt | 6.72B |
| Net Cash | -4.34B |
| Net Cash Per Share | -$29.66 |
| Equity (Book Value) | 16.72B |
| Book Value Per Share | 114.65 |
| Working Capital | 1.93B |
Cash Flow
In the last 12 months, operating cash flow was $2.88 billion and capital expenditures -$153.70 million, giving a free cash flow of $2.72 billion.
| Operating Cash Flow | 2.88B |
| Capital Expenditures | -153.70M |
| Free Cash Flow | 2.72B |
| FCF Per Share | $18.59 |
Margins
Gross margin is 76.12%, with operating and profit margins of 24.00% and 16.87%.
| Gross Margin | 76.12% |
| Operating Margin | 24.00% |
| Pretax Margin | 19.70% |
| Profit Margin | 16.87% |
| EBITDA Margin | 30.96% |
| EBIT Margin | 24.00% |
| FCF Margin | 28.13% |
Dividends & Yields
Biogen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.21% |
| Shareholder Yield | n/a |
| Earnings Yield | 7.83% |
| FCF Yield | 13.06% |
Analyst Forecast
The average price target for Biogen is $220.50, which is 54.81% higher than the current price. The consensus rating is "Buy".
| Price Target | $220.50 |
| Price Target Difference | 54.81% |
| Analyst Consensus | Buy |
| Analyst Count | 27 |
| Revenue Growth Forecast (5Y) | 0.01% |
| EPS Growth Forecast (5Y) | 10.15% |
Stock Splits
The last stock split was on January 18, 2001. It was a forward split with a ratio of 3:1.
| Last Split Date | Jan 18, 2001 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Biogen has an Altman Z-Score of 3.26 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.26 |
| Piotroski F-Score | 6 |